Haixi Pharma

Fujian Haixi Pharmaceutical Co., Ltd. (Haixi Pharma) is a China-based pharmaceutical company specializing in the research, development, and manufacturing of innovative small molecule drugs and high-end generic formulations. Founded in 2012 and headquartered in Fuzhou, the company focuses on therapeutic areas including gastroenterology, cardiovascular diseases, and anti-infectives. Haixi Pharma is best known for developing Tegoprazan (Keverprazan), a novel potassium-competitive acid blocker (P-CAB) that has been approved in China for the treatment of acid-related disorders. The company maintains an integrated business model that spans from drug discovery and clinical development to large-scale GMP manufacturing. Haixi Pharma's pipeline includes several Class 1 innovative drugs and improved new drugs aimed at addressing significant unmet medical needs in the domestic market. Through strategic partnerships, such as its collaboration with Luoxin Pharmaceuticals, the company has successfully transitioned into a commercial-stage player in the Chinese healthcare sector.